Cronos Group Inc.

NASDAQ:CRON

Drug Manufacturers - Specialty & Generic

Healthcare
$3.17 -0.56%

-$0.02 today

Market cap
$1.16B
Beta
1.25
P/E (TTM)
-488.3
EPS (TTM)
-$0.01
52W Low $1.84High $3.43

Volume 1.13M

Average 1.51M

CRON Sales of Investments

Cash received from selling or redeeming investments.

Cronos Group Inc.NASDAQ: CRON

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments outflow grows to $39.45M

Q1 FY2026 sales of investments was $39.45M, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $39.45M. Over 3 fiscal years it compounded at -73.2% a year.

Context

  • Sales of investments amounted to 3.5% of revenue in FY2025, down 151.2 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly sales of investments holds near $39.45M or moves back toward the trailing-twelve-month quarterly average of $9.86M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$39.45M— QoQ
Last fiscal yearDec 2025
$5.15M-97.2% YoY
LTMMar 2026
$39.45M+1391.2% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-97.2%——
3-year CAGR-73.2%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
5.15M USD
Year-over-year change
-97.2%
4-year CAGR
-60.7%

Sales of Investments vs competitors

How CRON compares with its peers on the latest reported figures

  • CRON's LTM Mar 2026 sales of investments of $39.45M is the 8th largest of the 11 companies compared; the peer median is $124.64M.
  • Its year-over-year change of +1391.2% is the 2nd highest of 8, against a peer median of -16.6%.
  • Sales of investments amounts to 19.2% of revenue for CRON, versus a peer median of 10.8%.
CRON Competitors Peer median
Sales of Investments for CRON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$614.95M +3.0%+30.4%87.6%
XNCRXencor, Inc.LTM Jun 2026$385.46M -16.6%+11.7%367.2%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$227.98M +3713.6%——
PCRXPacira BioSciences, Inc.LTM Mar 2026$222.13M +8.1%+4.2%30.2%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$171.77M -36.5%—858.8%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$77.51M -27.4%+47.8%10.8%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$68.17M -22.6%—8.6%
CRONCronos Group Inc.LTM Mar 2026$39.45M +1391.2%-73.2%19.2%
IRMDIRadimed CorporationLTM Mar 2026$0 ——0.0%
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
EMBCEmbecta Corp.LTM Mar 2026$0 ——0.0%
Peer median (excluding CRON) $124.64M-16.6%+21.0%10.8%

Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(397.2M)(168.73M)(74.55M)40.02M(2.93M)
Depreciation & Amortization15.4M13.12M8.11M9.34M14.48M
Deferred Income Tax00000
Stock-Based Compensation10.15M15.12M8.77M8.7M7.05M
Change in Working Capital(4.84M)15.66M(26.47M)(311K)(35.02M)
Accounts Receivables(12.16M)(8.55M)(6.59M)(917K)(26.2M)
Inventory11.57M(7.22M)7.4M5.28M(10.58M)
Accounts Payables(1.6M)(863K)(773K)(7.45M)1.13M
Other Working Capital(2.65M)32.29M(26.51M)2.77M636.96K
Other Non-Cash Items222.88M35.89M41.31M(38.9M)42.73M
Operating Cash Flow(153.62M)(88.95M)(42.84M)18.84M26.32M
Capital Expenditures(12.26M)(5.03M)(3.42M)(13.15M)(26.17M)
Acquisitions (Net)0005.71M2.9M
Purchases of Investments(230M)(271.38M)(608.25M)(8.34M)(59.44M)
Sales of Investments215.3M268.87M532.84M181.9M5.15M
Other Investing Activities(3.06M)4.12M18.42M8.41M0
Investing Cash Flow(28.9M)(1.84M)(59.5M)175.15M(77.9M)
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased0000(9.91M)
Dividends Paid00000
Other Financing Activities(13.44M)(2.9M)(1.03M)(1.23M)(10.34M)
Financing Cash Flow(13.44M)(2.9M)(1.03M)(1.23M)(20.25M)
Effect of Forex Changes4.91M(28.64M)8.01M(3.25M)3.89M
Net Change in Cash(191.05M)(122.33M)(95.35M)189.51M(67.94M)
Free Cash Flow(165.88M)(93.98M)(46.26M)5.69M151.61K

Cronos Group Inc.

NASDAQ:CRON

Intrinsic Alpha fair value

Locked

Current Price

$3.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.